Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890825 · ClinicalTrials.gov registry record · Phase 2
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 20
- Study locations
NCT00890825: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
NCT00890825 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by AstraZeneca. The registered enrollment target is 88 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00890825, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
Primary Outcome
OS was calculated as the interval from the date of randomisation to the date of patient death (any cause). Patients who had not died at the time of the final analysis, or who withdrew consent, were censored at the last date the patient was known to be alive.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG docetaxel
- DRUG AZD6244
Study Locations (20)
Other
- Research Site - Brussels
- Research Site - Charleroi
- Research Site - Edegem
- Research Site - Leuven
- Research Site - Liège
- Research Site - Liège
- Research Site - Belo Horizonte
- Research Site - Ijuí
- Research Site - Porto Alegre
- Research Site - Rio de Janeiro
- Research Site - Santo André
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - Plovdiv
- Research Site - Sofia
California
- Research Site - Los Angeles
Colorado
- Research Site - Aurora
Massachusetts
- Research Site - Boston
Ohio
- Research Site - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2009-04-20 |
| Est. Completion | 2016-11-02 |
| Phase | Phase 2 |
What the finished NCT00890825 record still lists
NCT00890825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00890825 names 20 study sites across 5 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00890825 about?
NCT00890825 is a clinical study titled "AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients". The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
What is the current status of trial NCT00890825?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2009-04-20. Estimated completion is 2016-11-02.
What conditions does trial NCT00890825 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00890825?
The interventions under investigation include: Placebo (DRUG), docetaxel (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00890825?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00890825 being conducted?
This trial has 20 study locations across California, Colorado, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00890825's enrollment target sits among peer trials
88 257th of 454 higher than 198 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI